Stryker Corporation (SYK) is well poised for growth, backed by a robust robotic arm-assisted surgery platform, Mako, and a diversified product portfolio. Meanwhile, improvement in price also buoys optimism.Shares of this currently Zacks Rank #3 (Hold) company have risen 16.4% in the past year compared with the industry’s 1.7% growth. The S&P 500 Index has increased 23.8% in the same time frame.Stryker, with a market capitalization of $112.54 billion, is one of the world’s largest medical device companies op ...

Stryker Corporation (NYSE:SYK) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 1:20 PM ET Company Participants Glenn Boehnlein - CFO Jason Beach - Head, IR Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Stryker this afternoon. We have Glenn Boehnlein, CFO; and Jason Beach, who heads Investor Relations. I'm Vijay Kumar, I cover Medtech and Life Sciences at Evercore. Glenn, Jason, thanks for taking the time. Question-and-Answer Session Q - Vijay Kumar So you guys had a pre ...

Stryker Corporation (NYSE:SYK) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Jason Beach - VP, IR Glenn Boehnlein - VP & CFO Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Andrew Ranieri - Morgan Stanley Philip Chickering - Deutsche Bank Robert Marcus - JPMorgan Chase & Co. Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Shagun Chadha - RBC Capital Markets Matthew O’Brien - Piper Sandler & Co. Ryan Zimmer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION (Exact name of registrant as specified in its charter) | Michigan | | 38-1239739 | | --- | --- | --- | | (State of incorporation) | | (I.R.S. ...

Stryker Corporation (NYSE:SYK) Wells Fargo Securities Healthcare Conference Call September 7, 2023 3:00 PM ET Company Participants Glenn Boehnlein - CFO Jason Beach - VP, IR Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen I'm Larry Biegelsen, the medical device analyst at Wells Fargo and it's my pleasure to host this session with Stryker. From the company, we have Glenn Boehnlein, the CFO; and Jason Beach, the Vice President of Investor Relations. In terms of format, it's going to ...

Stryker Corporation (NYSE:SYK) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET Company Participants Kevin Lobo - Chair and CEO Glenn Boehnlein - CFO Jason Beach - VP, IR Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Matthew O’Brien - Piper Sandler Ryan Zimmerman - BTIG Shagun Singh - RBC Eric Anderson - TD Cowen Matt Miksic - Barclays Joanne Wuensch - Citibank Rick Wise - Stifel Travis Steed - Bank of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION (Exact name of registrant as specified in its charter) | Michigan | | 38-1239739 | | --- | --- | --- | | (State of incorporation) | | (I.R.S. Emplo ...

Financial Data and Key Metrics Changes - The company reported adjusted EPS of $2.14, reflecting an 8.6% growth compared to the first quarter of 2022 [3][10] - Organic sales growth was 13.6% in the quarter, with US organic sales growth at 12.6% and international organic sales growth at 16.6% [10][100] - Adjusted gross margin was 63.2%, approximately 90 basis points unfavorable from the first quarter of 2022, primarily due to increased manufacturing and supply chain costs [13] - Adjusted operating margin was 21.1% of sales, approximately 70 basis points unfavorable to the first quarter of 2022 [14] Business Line Data and Key Metrics Changes - Endoscopy had US organic sales growth of 16.2%, driven by strong growth across major businesses [11] - Medical had US organic sales growth of 13.2%, benefiting from improved product supply [11] - Orthopedics and Spine had constant currency sales growth of 15.1%, with US organic growth of 13.3% and international growth of 20.3% [12] - Instruments had US organic sales growth of 8.9%, led by double-digit growth in the Surgical Technology business [107] Market Data and Key Metrics Changes - The international business continued to be a growth engine, with strong results in Europe, Australia, Canada, and Japan, while China experienced negative growth due to COVID and volume-based procurement [100][108] - The US Other Orthopedics segment declined organically by 14.8%, primarily due to a shift towards more rentals related to Mako installations [109] Company Strategy and Development Direction - The company is focused on maintaining a strong order book for capital equipment and is optimistic about the ongoing product super cycle [104][138] - Management emphasized the importance of innovation and product launches, including the Neptune S waste management system and the Mako 2.0 software [7][130] - The company plans to continue pursuing acquisitions as a key part of its growth strategy, with a focus on smaller tuck-in deals for the current year [45][161] Management's Comments on Operating Environment and Future Outlook - Management noted a gradual improvement in component availability and lessened supply chain constraints [3] - The company expects full-year organic sales growth to be in the range of 8% to 9%, with adjusted EPS guidance raised to $10.05 to $10.25 [101][112] - Management remains cautious about inflationary pressures and the potential impact of foreign exchange rates on sales and EPS [138] Other Important Information - The company ended the first quarter with $1.8 billion in cash and marketable securities and total debt of $13.1 billion [111] - Adjusted R&D spending was 6.5% of sales, a decrease from the previous year, while adjusted SG&A was 35.6% of sales, reflecting normalization of sales force expansion [110] Q&A Session Summary Question: What are the growth rates in Q1 for Ortho and MedSurge? - Management indicated that the procedures are ramping nicely and capital demand remains strong, contributing to optimism for the full year [113] Question: Can you provide insights on the performance of the knee and hip business? - The knee business continues to show strong performance, driven by Mako growth and cementless growth, while the hip business is expected to grow above market due to the Insignia Stem launch [116][178] Question: What is the outlook for the ASC market? - Management noted steady progression in both hips and knees, with double-digit penetration expected to continue as more procedures move to ASCs [25] Question: How is the company addressing competitive pressures in the Mako business? - Management acknowledged competitive pressures have shifted customer behavior but emphasized that they are winning at a high rate and installations are being utilized effectively [186] Question: What is the company's approach to acquisitions? - The company is focusing on smaller tuck-in acquisitions for the current year, with plans to pursue larger deals in the future if cash flow remains strong [161]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION (Exact name of registrant as specified in its charter) | Michigan | | | 38-1239739 | | --- | --- | --- | --- | | (State of incorporation) | | | (I.R.S. ...